IDS/ #2
JL 2/5/02

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, Washington, D.C. 20231, on

January 8, 2002
Date of Deposit

Justin B. Rand, Reg. No. 48,552
Name of Applicant, Assignee or
Registered Representative

Signature

1/8/02
Date of Signature

Our Case No.: 10402/15

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dr. Christor Westenfelder

Serial No.: 10/003,352

Filing Date: November 1, 2001

For: METHOD OF USE OF ERYTHROPOIETIN TO TREAT ISCHEMIC ACUTE RENAL FAILURE

Examiner: To Be Assigned

Group Art Unit No.: TBA

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

US PATENT

	DOCUMENT NUMBER	DATE	NAME
A1	6,274,158 B1	08/14/01	Czeizler

OTHER ART REFERENCES

A2	Adamson, J., et al., "Erythropoietin for End-Stage Renal Disease," The New England Journal of Medicine, Vol. 339, August 27, 1998, pp. 625-726.
A3	Allgren, R., et al., "Anaritide in Acute Tubular Necrosis," The New England Journal of Medicine, Vol. 336, No. 12, March 20, 1997, pp. 828-834.
A4	Allon, M., "Renal Abnormalities is Sickle Cell Disease," Arch Intern Med, Vol. 150, March 1990, pp. 501-504.
A5	Bacallao, R., et al., "Molecular Events in the Organization of Renal Tubular Epithelium: From Nephrogenesis to Regeneration," American Physiological Society Editorial Review, 1989, pp. F913-F924.
A6	Bachmann, S., et al., "Co-localization of Erythropoietin mRNA and Ecto-5'-Nucleotidase Immunoreactivity in Pertibular Cells of Rat Renal Cortex Indicates That Fibroblasts Produce Erythropoietin," The Journal of Histrochemistry and Cytochemistry, Vol. 41, No. 3, 1993, pp. 335-341.
A7	Banerjee, D., et al., "Exposure of Endothelial Cells to Recombinant Human Erythropoietin Induces Nitric Oxide Synthase Activity, " Kidney International, Vol. 57, 2000, pp. 1895-1904.
A8	Beeri, R., et al., "Rapid DNA Fragmentation from Hypoxia Along the Thick Ascending Limb of Rat Kidneys," Kidney International, Vol. 47, 1995, pp. 1806-1810.
A9	Bonventre, J., "Pathogenetic and Regenerative Mechanisms in Acute Tubular Necrosis," Kidney Blood Press Res, 1998, Vol. 21, pp. 226-229.
A10	Bonventre, J., et al., "Acute Renal Failure. I. Relative Importance of Proximal vs. Distal Tubular Injury," American Physiological Society Acute Renal Failure Forum, 1998, pp. F623-F631.
A11	Bonventre, J., "Mechanisms of Ischemic Acute Renal Failure," Kidney International, Vol. 43, 1993, pp. 1160-1178.
A12	Boom, H., et al., "Delayed Graft Function Influences Renal Function, But Not Survival," Kidney International, Vol. 58, 2000, pp. 859-866.
A13	Chertow, G., et al., "Independent Association Between Acute Renal Failure and Mortality Following Cardiac Surgery," The American Journal of Medicine, Vol. 104, April 1998, pp. 343-348.
A14	Cohen, G., "Caspases: The Executioners of Apoptosis," Biochem, Vol. J., 1997, pp. 1-16.
A15	Conger, J., "Interventions in Clinical Acute Renal Failure: What Are the Data?" American Journal of Kidney Diseases, Vol. 26, No. 4, October 1995, pp. 565-576.
A16	Daemen, M., et al., "Inhibition of Apoptosis Induced by Ischemia-reperfusion Prevents Inflammation," The Journal of Clinical Investigation, Vol. 104, No. 5, September 1999, pp. 541-549.
A17	Eckardt, K., et al., "Distribution of Erythropoietin Producing Cells in Rat Kidneys During Hypoxic Hypoxia," Kidney International, Vol. 43, 1993, pp. 815-823.
A18	Eschbach, J., "The Future of r-HuEPO," Nephrology Dialysis Transplantation, Vol. 10, No. 2 (suppl), 1995, pp. 96-109.
A19	Frede, S., et al., "Erythropoietin Gene Expression is Suppressed After Lipopolysaccharide or Interleukin-1B Injections in Rats," American Physiological Society, 1997, pp. R1067-R1071.
A20	Gregoli, P., et al., "The Roles of Bcl-X_L and Apopain in the Control of Erythropoiesis by Erythropoietin," Blood, Vol. 90, No. 2, July 15, 1997, pp. 630-640.
A21	Gregoli, P., et al., "Function of Caspases in Regulating Apoptosis Caused by Erythropoietin Deprivation in Erythroid Progenitors," Journal of Cellular Physiology, Vol. 178, 1999, pp. 133-143.

A22	Hammerman, M., et al., "Therapeutic Use of Growth Factors in Renal Failure," Journal of the American Society of Nephrology, Vol. 5, No. 1, 1994, pp. 1-11.
A23	Heidenreich, S., et al., "Direct Vasopressor Effect of Recombinant Human Erythropoietin on Renal Resistance Vessels," Kidney International, Vol. 39, 1991, pp. 259-265.
A24	Hirschberg, R., et al., "Multicenter Clinical Trial of Recombinant Human Insulin-like Growth Factor I In Patients with Acute Renal Failure," Kidney International, Vol. 55, 1999, pp. 2423-2432.
A25	Horiguchi, H., et al., "Cadmium and Platinum Suppression of Erythropoietin Production in Cell Culture: Clinical Implications," Blood, Vol. 96, No. 12, December 1, 2000, pp. 3743-2747.
A26	Huang, C., et al., "Study of the Actions of Human Recombinant Erythropoietin on Rat Renal Haemodynamics," Clinical Science, Vol. 83, 1992, pp. 453-459.
A27	Humes, D., "Acute Renal Failure: Prevailing Challenges and Prospects for the Future," Kidney International, Vol. 48, No. 50 (suppl), 1995, pp. S-26-S-32.
A28	Jelkmann, W., "Erythropoietin: Structure, Control of Production, and Function," American Physiological Society, Vol. 72, April 1992, pp. 449-489
A29	Juul, S., et al., "Tissue Distribution of Erythropoietin and Erythropoietin Receptor in the Developing Human Fetus," Early Human Development, Vol. 52, 1998, pp. 235-249.
A30	Kartha, S., et al., "Adenine Nucleotides Stimulate Migration in Wounded Cultures of Kidney Epithelial Cells," American Society for Clinical Investigation, Vol. 90, July 1992, pp. 288-292.
A31	Kelly, K., et al., "Acute Renal Failure in the New Millenium: Time to Consider Combination Therapy," Seminars in Nephrology, Vol. 20, No. 1, January 2000, pp. 4-19.
A32	Koury, S., et al., "Quantitation of Erythropoietin-Producing Cells in Kidneys of Mice by In Situ Hybridization: Correlation With Hematocrit, Renal Erythropoietin mRNA, and Serum Erythropoietin Concentration," Blood, Vol. 74, No. 2, August 1, 1989, pp. 645-651.
A33	Krantz, S., "Erythropoietin," Blood, Vol. 77, No. 3, February 1, 1991, pp. 419-434.
A34	Kriz, W., et al., "Structural Organization of the Mammalian Kidney," The Kidney: Physiology and Pathophysiology, 2nd Ed., 1992, pp. 707-777.
A35	Lacombe, C., et al., "Peritubular Cells Are the Site of Erythropoietin Synthesis in the Murine Hypoxic Kidney," the American Society for Clinical Investigation, Vol. 81, February 1998, pp. 620-623.
A36	Lieberthal, W., et al., "Graded ATP Depletion Can Cause Necrosis or Apoptosis of Cultured Mouse Proximal Tubular Cells," the American Physiological Society, 1998, pp. F315-F327.
A37	Lieberthal, W., et al., "Necrosis and Apoptosis in Acute Renal Failure," Seminars in Nephrology, Vol. 18, No. 5, September 1998, pp. 505-518.
A38	Maher, E., et al., "Prognosis of Critically-ill Patients with Acute Renal Failure: APACHE II Score and Other Predictive Factors," Quarterly Journal of Medicine, New Series 72, No. 269, September 1989, pp. 857-866
A39	Matas, A., et al., "Immunologic and Nonimmunologic Factors," Transplantation, Vol. 69, No. 1, January 15, 2000, pp. 54-58.
A40	Maxwell, P., et al., "Identification of the Renal Erythropoietin-Producing Cells Using Transgenic Mice," Kidney International, Vol. 44, 1993, pp. 1149-1162.
A41	McWhinnie, D., et al., "Morphometric Analysis of Cellular Infiltration Assessed by Monoclonal Antibody Labeling in Sequential Human Renal Allograft Biopsies," Transplantation, Vol. 42, No. 4, October 1986, pp. 352-358.
A42	Miller, S., et al., "Effects on IGF-I on Renal Function in End-Stage Chronic Renal Failure," Kidney International, Vol. 46, 1994, pp. 201-207.
A43	Molitoris, B., et al., "Cellular ATP Depletion Induces Disruption of the Spectrin Cytoskeletal Network," Veterans Affairs Research Service, 1996, pp. F790-F798.
A44	Molitoris, B., et al., "The Role of Cell Adhesion Molecules in Ischemic Acute Renal Failure," The American Journal of Medicine, Vol. 106, May 1999, pp. 583-592.
A45	Muirhead, N., " Erythropoietin and Renal Transplantation." Kidney International, Vol. 55, No. 69 (suppl), 1999, pp. S-86-S-92.
A46	Nemoto, T., et al., "Recombinant Erythropoietin Rapidly Treats Anemia in Ischemic Acute Renal Failure," Kidney International, Vol. 59, 2001, pp. 246-251.
A47	Nielsen, O., et al., "Erythropoietin Deficiency in Acute Tubular Necrosis," Journal of Internal Medicine, Vol. 227, 1990, pp. 373-380.

A48	Nogae, S., et al., "Induction of Apoptosis in Ischemia-Reperfusion Kidney Model: Appearance of DNA Strand Breaks and Expression of FAS mRNA," Journal of American Society of Nephrology, Vol. 5, 1994, pp. 905a.
A49	Nushiro, N., et al., "Recombinant Human Erythropoietin Stimulates Tubular Reabsorption of Sodium in Anesthetized Rabbits," Hypertens Res, Vol. 18, No. 3, 1995, pp. 203-207.
A50	Ortiz, A., et al., "Apoptosis-Related Fas RNA is Expressed by Renal Cells and Increased in Renal Damage," Journal of American Society of Nephrology, Vol. 4, 1993, pp.496a.
A51	O'Shea, M., et al., "Growth Hormone and the Kidney: A Case Presentation and Review of the Literature," Journal of the American Society of Nephrology, Vol. 3, No. 2, 1992, pp. 157-161.
A52	O'Shea, M., et al., "Effects of IGF-I on Renal Function in Patients with Chronic Renal Failure," the American Physiological Society, 1993, pp. F917-F922.
A53	Prommool, S., et al., "Time Dependency of Factors Affecting Renal Alograft Survival," Journal of the American Society of Nephrology, Vol. 11, 2000, pp. 565-573.
A54	Sawyer, S. et al., "The Functional Form of the Erythropoietin Receptor is a 78-kDa Protein: Correlation with Cell Surface Expression, Endocytosis, and Phosphorylation," Proc. Natl. Acad. Sci., Vol. 90, July 1993, pp. 6849-6853.
A55	Schelling, J., et al., "Fas-Dependent Fratricidal Apoptosis Is a Mechanism of Tubular Epithelial Cell Depletion in Chronic Renal Failure," Case Western Reserve University School of Medicine, Cleveland, Ohio, 1997, pp. 12.
A56	Schumer, M., et al., "Morphologic, Biochemical, and Molecular Evidence of Apoptosis During the Reperfusion Phase After Brief Periods of Renal Ischemia," American Journal of Pathology, Vol. 140, No. 4, April 1992, pp. 831-838.
A57	Shimizu, A., et al., "Apoptosis and Cell Desquamation in Repair Process of Ischemic Tubular Necrosis," Virchows Archiv B Cell Pathology, Vol. 64, 1993, pp. 171-180.
A58	Siren, A., et al., "Erythropoitin Prevents Neuronal Apoptosis After Cerebral Ischemia and Metabolic Stress," PNAS, Vol. 98, No. 7, March 27, 2001, pp. 4044-4049.
A59	Star, R., "Treatment of Acute Renal Failure," Kidney International, Vol. 54, 1998, pp. 1817-1831.
A60	Tan, C., et al., "Erythropoietin Production in Rats with Post-Ischemic Acute Renal Failure," Kidney International, Vol. 50, 1996, pp. 1958-1964.
A61	Toback, F., "Regeneration After Acute Tubular Necrosis," Kidney International, Vol. 41, 1992, pp. 226-246.
A62	Vaziri, N., et al., "Erythropoietin Enhances Recovery from Cisplatin-Induced Acute Renal Failure," the American Physiological Society, 1994, pp. F360-F366.
A63	Venekatachalam, M., et al., "Ischemic Damage and Repair in the Rat Proximal Tubule: Differences Among the S_1, S_2, and S_3 Segments." Kidney International, Vol. 14, 1978, pp. 31-49.
A64	Weinberg, J., "The Cell Biology of Ischemic Renal Injury," Kidney International, Vol. 39, 1991, pp. 476-500.
A65	Westenfelder, C., "Mitogenic and Motogenic Actions of Erythropoietin (EPO) on Tubular Cells Appear To Accelerate Functional Recovery from Ischemic Acute Renal Failure (ARF) in Rats." Journal of American Society of Nephrology, Vol. 11, 2000, pp. 597a.
A66	Westenfelder, C., et al., "Renal Tubular Function in Glycerol-Induced Acute Renal Failure," Kidney International, Vol. 18, 1980, pp. 432-444.
A67	Westenfelder, C., et al., "Anti-Apoptotic, Mitogenic and Motogenic Actions of Erthropoietin on Tubular Cells Protect Renal Function and Accelerate Recovery From Ischemic Acute Renal Failure in Rats," Kidney International, Vol. 49, No. 1, January 2001, pp. 319.
A68	Westenfelder, C., et al., "Human, Rat, and Mouse Kidney Cells Express Functional Erythropoietin Receptors," Kidney International, Vol. 55, 1999, pp. 808-820.
A69	Westenfelder, C., et al., "Erythropoietin Stimulates Proliferation of Human Renal Carcinoma Cells," Kidney International, Vol. 58, 2000, pp. 647-657.
A70	Witzhall, R., et al., "Localization of Proliferating Cell Nuclear Antigen, Vimentin, c-Fos, and Clusterin in the Postischemic Kidney," Journal of Clinical Investigations, Vol. 93, May 1994, pp. 2175-2188.
A71	Wood, P., et al., "Cisplatin-Associated Anemia: An Erthropoietin Deficiency Syndrome," Journal of Clinical Investigations, Vol. 95, April 1995, pp. 1650-1659.

A72	Yaoita, H., et al., "Attenuation of Ischemia/Reperfusion Injury in Rats by a Caspase Inhibitor," American Heart Association, Vol. 97, 1998, pp. 276-281.
A73	Youssoufian, H., et al., "Structure, Function, and Activation of the Erythropoietin Receptor," Blood, Vol. 81. No. 9, May 1, 1993, pp. 2223-2236.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,

Justin Rand
Registration No. 48,552
Attorney for Applicant

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
Tel. (312) 321-4200
Fax (312) 321-4299

FORM PTO-1449	SERIAL NO. 10/003,352	CASE NO. 10402/15
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 1, 2002	GROUP ART UNIT TBA
(use several sheets if necessary)	APPLICANT(S): Dr. Christof Westenfelder	

EXAMINER INITIAL		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
	A14	Cohen, G., "Caspases: The Executioners of Apoptosis," Biochem, Vol. J., 1997, pp. 1-16.
	A15	Conger, J., "Interventions in Clinical Acute Renal Failure: What Are the Data?" American Journal of Kidney Diseases, Vol. 26, No. 4, October 1995, pp. 565-576.
	A16	Daemen, M., et al., "Inhibition of Apoptosis Induced by Ischemia-reperfusion Prevents Inflammation," The Journal of Clinical Investigation, Vol. 104, No. 5, September 1999, pp. 541-549.
	A17	Eckardt, K., et al., "Distribution of Erythropoietin Producing Cells in Rat Kidneys During Hypoxic Hypoxia," Kidney International, Vol. 43, 1993, pp. 815-823.
	A18	Eschbach, J., "The Future of r-HuEPO," Nephrology Dialysis Transplantation, Vol. 10, No. 2 (suppl), 1995, pp. 96-109.
	A19	Frede, S., et al., "Erythropoietin Gene Expression is Suppressed After Lipopolysaccharide or Interleukin-1B Injections in Rats," American Physiological Society, 1997, pp. R1067-R1071.
	A20	Gregoli, P., et al., "The Roles of Bcl-X_L and Apopain in the Control of Erythropoiesis by Erythropoietin," Blood, Vol. 90, No. 2, July 15, 1997, pp. 630-640.
	A21	Gregoli, P., et al., "Function of Caspases in Regulating Apoptosis Caused by Erythropoietin Deprivation in Erythroid Progenitors," Journal of Cellular Physiology, Vol. 178, 1999, pp. 133-143.
	A22	Hammerman, M., et al., "Therapeutic Use of Growth Factors in Renal Failure," Journal of the American Society of Nephrology, Vol. 5, No. 1, 1994, pp. 1-11.
	A23	Heidenreich, S., et al., "Direct Vasopressor Effect of Recombinant Human Erythropoietin on Renal Resistance Vessels," Kidney International, Vol. 39, 1991, pp. 259-265.
	A24	Hirschberg, R., et al., "Multicenter Clinical Trial of Recombinant Human Insulin-like Growth Factor I In Patients with Acute Renal Failure," Kidney International, Vol. 55, 1999, pp. 2423-2432.
	A25	Horiguchi, H., et al., "Cadmium and Platinum Suppression of Erythropoietin Production in Cell Culture: Clinical Implications," Blood, Vol. 96, No. 12, December 1, 2000, pp. 3743-2747.
	A26	Huang, C., et al., "Study of the Actions of Human Recombinant Erythropoietin on Rat Renal Haemodynamics," Clinical Science, Vol. 83, 1992, pp. 453-459.
	A27	Humes, D., "Acute Renal Failure: Prevailing Challenges and Prospects for the Future," Kidney International, Vol. 48, No. 50 (suppl), 1995, pp. S-26-S-32.
	A28	Jelkmann, W., "Erythropoietin: Structure, Control of Production, and Function," American Physiological Society, Vol. 72, April 1992, pp. 449-489
	A29	Juul, S., et al., "Tissue Distribution of Erythropoietin and Erythropoietin Receptor in the Developing Human Fetus," Early Human Development, Vol. 52, 1998, pp. 235-249.
	A30	Kartha, S., et al., "Adenine Nucleotides Stimulate Migration in Wounded Cultures of Kidney Epithelial Cells," American Society for Clinical Investigation, Vol. 90, July 1992, pp. 288-292.
	A31	Kelly, K., et al., "Acute Renal Failure in the New Millenium: Time to Consider Combination Therapy," Seminars in Nephrology, Vol. 20, No. 1, January 2000, pp. 4-19.
	A32	Koury, S., et al., "Quantitation of Erythropoietin-Producing Cells in Kidneys of Mice by In Situ Hybridization: Correlation With Hematocrit, Renal Erythropoietin mRNA, and Serum Erythropoietin Concentration," Blood, Vol. 74, No. 2, August 1, 1989, pp. 645-651.
	A33	Krantz, S., "Erythropoietin," Blood, Vol. 77, No. 3, February 1, 1991, pp. 419-434.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. 10/003,352	CASE NO. 10402/15
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 1, 2002	GROUP ART UNIT TBA
(use several sheets if necessary)	APPLICANT(S): Dr. Christof Westenfelder	

REFERENCE DESIGNATION **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A1	6,274,158 B1	08/14/01	Czeizler		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES	NO
	A						

EXAMINER INITIAL		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
	A2	Adamson, J., et al., "Erythropoietin for End-Stage Renal Disease," The New England Journal of Medicine, Vol. 339, August 27, 1998, pp. 625-726.
	A3	Allgren, R., et al., "Anaritide in Acute Tubular Necrosis," The New England Journal of Medicine, Vol. 336, No. 12, March 20, 1997, pp. 828-834.
	A4	Allon, M., "Renal Abnormalities is Sickle Cell Disease," Arch Intern Med, Vol. 150, March 1990, pp. 501-504.
	A5	Bacallao, R., et al., "Molecular Events in the Organization of Renal Tubular Epithelium: From Nephrogenesis to Regeneration," American Physiological Society Editorial Review, 1989, pp. F913-F924.
	A6	Bachmann, S., et al., "Co-localization of Erythropoietin mRNA and Ecto-5'-Nucleotidase Immunoreactivity in Pertibular Cells of Rat Renal Cortex Indicates That Fibroblasts Produce Erythropoietin," The Journal of Histrochemistry and Cytochemistry, Vol. 41, No. 3, 1993, pp. 335-341.
	A7	Banerjee, D., et al., "Exposure of Endothelial Cells to Recombinant Human Erythropoietin Induces Nitric Oxide Synthase Activity, " Kidney International, Vol. 57, 2000, pp. 1895-1904.
	A8	Beeri, R., et al., "Rapid DNA Fragmentation from Hypoxia Along the Thick Ascending Limb of Rat Kidneys," Kidney International, Vol. 47, 1995, pp. 1806-1810.
	A9	Bonventre, J., "Pathogenetic and Regenerative Mechanisms in Acute Tubular Necrosis," Kidney Blood Press Res, 1998, Vol. 21, pp. 226-229.
	A10	Bonventre, J., et al., "Acute Renal Failure. I. Relative Importance of Proximal vs. Distal Tubular Injury," American Physiological Society Acute Renal Failure Forum, 1998, pp. F623-F631.
	A11	Bonventre, J., "Mechanisms of Ischemic Acute Renal Failure," Kidney International, Vol. 43, 1993, pp. 1160-1178.
	A12	Boom, H., et al., "Delayed Graft Function Influences Renal Function, But Not Survival," Kidney International, Vol. 58, 2000, pp. 859-866.
	A13	Chertow, G., et al., "Independent Association Between Acute Renal Failure and Mortality Following Cardiac Surgery," The American Journal of Medicine, Vol. 104, April 1998, pp. 343-348.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. 10/003,352	CASE NO. 10402/15
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 1, 2002	GROUP ART UNIT TBA
(use several sheets if necessary)	APPLICANT(S): Dr. Christof Westenfelder	

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
	A34	Kriz, W., et al., "Structural Organization of the Mammalian Kidney," The Kidney: Physiology and Pathophysiology, 2nd Ed., 1992, pp. 707-777.
	A35	Lacombe, C., et al., "Peritubular Cells Are the Site of Erythropoietin Synthesis in the Murine Hypoxic Kidney," the American Society for Clinical Investigation, Vol. 81, February 1998, pp. 620-623.
	A36	Lieberthal, W., et al., "Graded ATP Depletion Can Cause Necrosis or Apoptosis of Cultured Mouse Proximal Tubular Cells," the American Physiological Society, 1998, pp. F315-F327.
	A37	Lieberthal, W., et al., "Necrosis and Apoptosis in Acute Renal Failure," Seminars in Nephrology, Vol. 18, No. 5, September 1998, pp. 505-518.
	A38	Maher, E., et al., "Prognosis of Critically-ill Patients with Acute Renal Failure: APACHE II Score and Other Predictive Factors," Quarterly Journal of Medicine, New Series 72, No. 269, September 1989, pp. 857-866
	A39	Matas, A., et al., "Immunologic and Nonimmunologic Factors," Transplantation, Vol. 69, No. 1, January 15, 2000, pp. 54-58.
	A40	Maxwell, P., et al., "Identification of the Renal Erythropoietin-Producing Cells Using Transgenic Mice," Kidney International, Vol. 44, 1993, pp. 1149-1162.
	A41	McWhinnie, D., et al., "Morphometric Analysis of Cellular Infiltration Assessed by Monoclonal Antibody Labeling in Sequential Human Renal Allograft Biopsies," Transplantation, Vol. 42, No. 4, October 1986, pp. 352-358.
	A42	Miller, S., et al., "Effects on IGF-I on Renal Function in End-Stage Chronic Renal Failure," Kidney International, Vol. 46, 1994, pp. 201-207.
	A43	Molitoris, B., et al., "Cellular ATP Depletion Induces Disruption of the Spectrin Cytoskeletal Network," Veterans Affairs Research Service, 1996, pp. F790-F798.
	A44	Molitoris, B., et al., "The Role of Cell Adhesion Molecules in Ischemic Acute Renal Failure," The American Journal of Medicine, Vol. 106, May 1999, pp. 583-592.
	A45	Muirhead, N., " Erythropoietin and Renal Transplantation." Kidney International, Vol. 55, No. 69 (suppl), 1999, pp. S-86-S-92.
	A46	Nemoto, T., et al., "Recombinant Erythropoietin Rapidly Treats Anemia in Ischemic Acute Renal Failure," Kidney International, Vol. 59, 2001, pp. 246-251.
	A47	Nielsen, O., et al., "Erythropoietin Deficiency in Acute Tubular Necrosis," Journal of Internal Medicine, Vol. 227, 1990, pp. 373-380.
	A48	Nogae, S., et al., "Induction of Apoptosis in Ischemia-Reperfusion Kidney Model: Appearance of DNA Strand Breaks and Expression of FAS mRNA," Journal of American Society of Nephrology, Vol. 5, 1994, pp. 905a.
	A49	Nushiro, N., et al., "Recombinant Human Erythropoietin Stimulates Tubular Reabsorption of Sodium in Anesthetized Rabbits," Hypertens Res, Vol. 18, No. 3, 1995, pp. 203-207.
	A50	Ortiz, A., et al., "Apoptosis-Related Fas RNA is Expressed by Renal Cells and Increased in Renal Damage," Journal of American Society of Nephrology, Vol. 4, 1993, pp.496a.
	A51	O'Shea, M., et al., "Growth Hormone and the Kidney: A Case Presentation and Review of the Literature," Journal of the American Society of Nephrology, Vol. 3, No. 2, 1992, pp. 157-161.
	A52	O'Shea, M., et al., "Effects of IGF-I on Renal Function in Patients with Chronic Renal Failure," the American Physiological Society, 1993, pp. F917-F922.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. 10/003,352	CASE NO. 10402/15
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 1, 2002	GROUP ART UNIT TBA
(use several sheets if necessary)	APPLICANT(S): Dr. Christof Westenfelder	

EXAMINER INITIAL		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
	A53	Prommool, S., et al., "Time Dependency of Factors Affecting Renal Alograft Survival," Journal of the American Society of Nephrology, Vol. 11, 2000, pp. 565-573.
	A54	Sawyer, S. et al., "The Functional Form of the Erythropoietin Receptor is a 78-kDa Protein: Correlation with Cell Surface Expression, Endocytosis, and Phosphorylation," Proc. Natl. Acad. Sci., Vol. 90, July 1993, pp. 6849-6853.
	A55	Schelling, J., et al., "Fas-Dependent Fratricidal Apoptosis Is a Mechanism of Tubular Epithelial Cell Depletion in Chronic Renal Failure," Case Western Reserve University School of Medicine, Cleveland, Ohio, 1997, pp. 12.
	A56	Schumer, M., et al., "Morphologic, Biochemical, and Molecular Evidence of Apoptosis During the Reperfusion Phase After Brief Periods of Renal Ischemia," American Journal of Pathology, Vol. 140, No. 4, April 1992, pp. 831-838.
	A57	Shimizu, A., et al., "Apoptosis and Cell Desquamation in Repair Process of Ischemic Tubular Necrosis," Virchows Archiv B Cell Pathology, Vol. 64, 1993, pp. 171-180.
	A58	Siren, A., et al., "Erythropoitin Prevents Neuronal Apoptosis After Cerebral Ischemia and Metabolic Stress," PNAS, Vol. 98, No. 7, March 27, 2001, pp. 4044-4049.
	A59	Star, R., "Treatment of Acute Renal Failure," Kidney International, Vol. 54, 1998, pp. 1817-1831.
	A60	Tan, C., et al., "Erythropoietin Production in Rats with Post-Ischemic Acute Renal Failure," Kidney International, Vol. 50, 1996, pp. 1958-1964.
	A61	Toback, F., "Regeneration After Acute Tubular Necrosis," Kidney International, Vol. 41, 1992, pp. 226-246.
	A62	Vaziri, N., et al., "Erythropoietin Enhances Recovery from Cisplatin-Induced Acute Renal Failure," the American Physiological Society, 1994, pp. F360-F366.
	A63	Venekatachalam, M., et al., "Ischemic Damage and Repair in the Rat Proximal Tubule: Differences Among the S_1, S_2, and S_3 Segments." Kidney International, Vol. 14, 1978, pp. 31-49.
	A64	Weinberg, J., "The Cell Biology of Ischemic Renal Injury," Kidney International, Vol. 39, 1991, pp. 476-500.
	A65	Westenfelder, C., "Mitogenic and Motogenic Actions of Erythropoietin (EPO) on Tubular Cells Appear To Accelerate Functional Recovery from Ischemic Acute Renal Failure (ARF) in Rats." Journal of American Society of Nephrology, Vol. 11, 2000, pp. 597a.
	A66	Westenfelder, C., et al., "Renal Tubular Function in Glycerol-Induced Acute Renal Failure," Kidney International, Vol. 18, 1980, pp. 432-444.
	A67	Westenfelder, C., et al., "Anti-Apoptotic, Mitogenic and Motogenic Actions of Erthropoietin on Tubular Cells Protect Renal Function and Accelerate Recovery From Ischemic Acute Renal Failure in Rats," Kidney International, Vol. 49, No. 1, January 2001, pp. 319.
	A68	Westenfelder, C., et al., "Human, Rat, and Mouse Kidney Cells Express Functional Erythropoietin Receptors," Kidney International, Vol. 55, 1999, pp. 808-820.
	A69	Westenfelder, C., et al., "Erythropoietin Stimulates Proliferation of Human Renal Carcinoma Cells," Kidney International, Vol. 58, 2000, pp. 647-657.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. 10/003,352	CASE NO. 10402/15
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 1, 2002	GROUP ART UNIT TBA
(use several sheets if necessary)	APPLICANT(S): Dr. Christof Westenfelder	

EXAMINER INITIAL		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
	A70	Witzhall, R., et al., "Localization of Proliferating Cell Nuclear Antigen, Vimentin, c-Fos, and Clusterin in the Postischemic Kidney," Journal of Clinical Investigations, Vol. 93, May 1994, pp. 2175-2188.
	A71	Wood, P., et al., "Cisplatin-Associated Anemia: An Erthropoietin Deficiency Syndrome," Journal of Clinical Investigations, Vol. 95, April 1995, pp. 1650-1659.
	A72	Yaoita, H., et al., "Attenuation of Ischemia/Reperfusion Injury in Rats by a Caspase Inhibitor," American Heart Association, Vol. 97, 1998, pp. 276-281.
	A73	Youssoufian, H., et al., "Structure, Function, and Activation of the Erythropoietin Receptor," Blood, Vol. 81. No. 9, May 1, 1993, pp. 2223-2236.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.